1) Koyama H, Ohno Y, Kono A, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol 2008;18:2120-31.
2) Koyama H, Ohno Y, Aoyama N, et al. Comparison of STIR turbo SE imaging and diffusion-weighted imaging of the lung:capability for detection and subtype classification of pulmonary adenocarcinomas. Eur Radiol 2010;20:790-800.
3) Ohno Y, Koyama H, Yoshikawa T, et al. Pulmonary high-resolution ultrashort TE MR imaging:Comparison with thin-section standardand low-dose computed tomography for the assessment of pulmonary parenchyma diseases. J Magn Reson Imaging 2016;43:512-32.
4) Ohno Y, Koyama H, Yoshikawa T, et al. Standard-, Reduced-, and No-Dose Thin-Section Radiologic Examinations:Comparison of capability for nodule detection and nodule type assessment in patients suspected of having pulmonary nodules. Radiology 2017;284:562-73.
5) Allen BD, Schiebler ML, Sommer G, et al. Cost-effectiveness of lung MRI in lung cancer screening. Eur Radiol 2020;30:1738-46.
6) Ohno Y. New applications of magnetic resonance imaging for thoracic oncology. Semin Respir Crit Care Med 2014;35:27-40.
7) Ohno Y, Nishio M, Koyama H, et al. Dynamic contrast-enhanced CT and MRI for pulmonary nodule assessment. AJR Am J Roentgenol 2014;202:515-29.
8) Ciliberto M, Kishida Y, Seki S, et al. Update of MR Imaging for Evaluation of Lung Cancer. Radiol Clin North Am 2018;56:437-69.
9) Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma:report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.
10) Takahashi K, Furuse M, Hanaoka H, et al. Pulmonary vein and left atrial invasion by lung cancer:assessment by breath-hold gadolinium-enhanced three-dimensional MR angiography. J Comput Assist Tomogr 2000;24:557-61.
11) Ohno Y, Adachi S, Motoyama A, et al. Multiphase ECG-triggered 3D contrast-enhanced MR angiography:utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging 2001;13:215-24.
12) Ohno Y, Hatabu H, Takenaka D, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer:quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology 2004;231:872-9.
13) Ohno Y, Koyama H, Yoshikawa T, et al. N stage disease in patients with non-small cell lung cancer:efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusionweighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology 2011;261:605-15.
14) Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET:comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509.
15) Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging:efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008;248:632-42.
16) Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer:wholebody MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008;248:643-54.
17) Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients:comparison of whole-body diffusion-weighted imaging(DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30:298-308.
18) Ohno Y, Koyama H, Yoshikawa T, et al. Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging:TNM and stage assessment capability for non-small cell lung cancer patients. Radiology 2015;275:849-61.
19) Ohno Y, Koyama H, Lee HY, et al. Magnetic Resonance Imaging(MRI) and Positron Emission Tomography(PET)/MRI for Lung cancer staging. J Thorac Imaging 2016;31:215-27.